The Claim
In HIV-infected adults on suppressive antiretroviral therapy, daily administration of rosuvastatin (10 mg) for 48 weeks reduces the proportion of PD-1-expressing CD4+ and CD8+ T cells by 42.5% and 45.5%, respectively, compared to placebo, indicating a direct causal effect on T cell exhaustion markers.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with HIV who are on effective antiretroviral treatment, taking 10 mg of rosuvastatin daily for 48 weeks reduces the percentage of CD4+ and CD8+ T cells expressing PD-1 by 42.5% and 45.5%, respectively, compared to those taking a placebo.
See the scientific wording
In HIV-infected adults on suppressive antiretroviral therapy, daily rosuvastatin (10 mg) for 48 weeks reduces the proportion of PD-1-expressing CD4+ and CD8+ T cells by 42.5% and 45.5%, respectively, compared to placebo, indicating a direct causal effect on T cell exhaustion markers.
Rosuvastatin blocks a key enzyme in cholesterol production, which reduces molecules needed to activate certain signaling proteins in immune cells. This turns down inflammation in blood vessels and immune cells, leading to less stimulation of T cells. With less inflammation, T cells stop expressing exhaustion markers like PD-1 and regain normal function.
What the research says
1 studyThis study found that taking rosuvastatin daily for 48 weeks lowered a marker of immune fatigue (PD-1) on key immune cells in people with HIV who are already on effective treatment. This suggests the drug may help these immune cells recover their strength.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.